Serum Visfatin Levels and Tissue Visfatin Expression in Patients with Breast Diseases

Hande Koksal, Nevzat Serdar Ugras, Sevil Kurban, Ismail Harmankaya, Arif Atay, Meryem Ilkay Eren Karanis and Osman Dogru

Department of General Surgery, Konya Education and Research Hospital, Konya, Turkey
Department of Pathology, Selcuk University Faculty of Medicine, Konya, Turkey
Department of Biochemistry, Necmettin Erbakan University Faculty of Medicine, Konya, Turkey

^*Correspondance to: Hande Koksal 

 PDF  Full Text DOI: 10.25107/2474-1647.1601

Abstract

Objective: This study aims to evaluate if serum visfatin levels and tissue visfatin expression have an importance in patients with either benign or malign breast masses.Patients and
Methods: The patients with complaints of breast masses and have diagnosis of either invasive ductal carcinoma or fibroadenoma were enrolled. Serum visfatin levels were measured by ELISA and tissue visfatin expressions were evaluated by immunhistochemistry.Results: There were 29 patients with invasive ductal carcinoma and 14 patients with fibroadenoma. Immunhistochemical visfatin staining was positive in all patients with fibroadenoma and invasive carcinoma. When the patients with malignancy were evaluated separately, the patients with positive ER and PR were seen to have higher levels of serum visfatin than the patients with negative hormone receptors (p=0.023 and p=0.034 respectively). Serum visfatin levels were also high in patients with lymph node involvement and T2 tumors in diameter (p=0.04 and p=0.037 respectively).Discussion: Serum visfatin levels were high in patients with positive hormone receptors, nodal involvement and T2 tumors. Visfatin staining was positive in both benign and malign diseases of the breast; it is not possible to declare visfatin as a prognostic tool in breast cancer.

Keywords

Breast; Breast cancer; Visfatin

Cite the article

Koksal H, Ugras NS, Kurban S, Harmankaya I, Atay A, Karanis MIE. Serum Visfatin Levels and Tissue Visfatin Expression in Patients with Breast Diseases. Clin Surg. 2017; 2: 1601.